Genmab A/S (GMAB) News Today $26.87 -0.18 (-0.67%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$26.80 -0.07 (-0.25%) As of 05/22/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GMAB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 Time Period Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 CongressMay 21 at 5:00 PM | globenewswire.comGenmab (CPSE:GMAB) Valuation Check After Recent Share Price Softness And 24.6% Undervaluation EstimateMay 17, 2026 | finance.yahoo.comGenmab A/S (GMAB) Q1 2026 Earnings Call TranscriptMay 14, 2026 | seekingalpha.comGenmab A/S: Capital Increase in Genmab as a Result of Employee Warrant ExerciseMay 13, 2026 | finanznachrichten.de5 Most Promising Biotech Stocks to Buy NowMay 12, 2026 | insidermonkey.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseMay 12, 2026 | globenewswire.comGenmab A/S 2026 Q1 - Results - Earnings Call PresentationMay 10, 2026 | seekingalpha.comIs It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi‑Year Share PerformanceMay 8, 2026 | finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Shares Gap Down - Time to Sell?May 8, 2026 | marketbeat.comGenmab A/S Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comGenmab Announces Financial Results for the First Quarter of 2026May 7, 2026 | globenewswire.comWhat To Expect From Genmab AS (GMAB) Q1 2026 EarningsMay 6, 2026 | finance.yahoo.comGenmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesMay 4, 2026 | marketbeat.comWhat is HC Wainwright's Forecast for Genmab A/S Q2 Earnings?May 4, 2026 | marketbeat.comGenmab (GMAB) Rated Outperform on Oncology PipelineMay 3, 2026 | finance.yahoo.comOppenheimer Asset Management Inc. Acquires 48,894 Shares of Genmab A/S Sponsored ADR $GMABMay 2, 2026 | marketbeat.comHC Wainwright Has Lowered Expectations for Genmab A/S (NASDAQ:GMAB) Stock PriceApril 30, 2026 | marketbeat.comGenmab A/S (GMAB) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comPictet Asset Management Holding SA Takes $33.84 Million Position in Genmab A/S Sponsored ADR $GMABApril 30, 2026 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Raised to "Strong-Buy" at Truist FinancialApril 28, 2026 | marketbeat.comGenmab (CPSE:GMAB) Valuation Check After Mixed Recent Share PerformanceApril 20, 2026 | finance.yahoo.comGenmab A/S Share Capital ReductionApril 17, 2026 | globenewswire.comGenmab A (GMAB) price target decreased by 61.97% to 34.46April 16, 2026 | msn.comMajor Shareholder AnnouncementApril 14, 2026 | globenewswire.comGenmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2026April 14, 2026 | finanznachrichten.deGenmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026April 14, 2026 | globenewswire.comGenmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian CancerApril 13, 2026 | businesswire.comGenmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian CancerApril 13, 2026 | globenewswire.comWells Fargo Sticks to Its Buy Rating for Genmab (GMAB)April 11, 2026 | theglobeandmail.comGenmab: Multiple Binaries Could Alter The ThesisApril 9, 2026 | seekingalpha.comGenmab A/S Sponsored ADRApril 6, 2026 | edition.cnn.comA Look At Genmab’s (CPSE:GMAB) Valuation After Recent Share Price VolatilityApril 1, 2026 | finance.yahoo.comTransactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated PersonsApril 1, 2026 | globenewswire.comMajor Shareholder AnnouncementApril 1, 2026 | globenewswire.comMajor Shareholder AnnouncementMarch 30, 2026 | globenewswire.comWolfe Research initiates coverage of Genmab A (GMAB) with outperform recommendationMarch 28, 2026 | msn.comGenmab And Lundbeck Amlenetug Data Adds Nuance To Valuation DebateMarch 20, 2026 | finance.yahoo.comConstitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in GenmabMarch 19, 2026 | globenewswire.comPassing of Genmab A/S' Annual General MeetingMarch 19, 2026 | globenewswire.comCompletion of Share Buy-back ProgramMarch 16, 2026 | globenewswire.comGenmab A/S (GMAB) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptMarch 11, 2026 | seekingalpha.comGenmab A/S (GMAB) Presents at Leerink Global Healthcare Conference 2026 TranscriptMarch 10, 2026 | seekingalpha.comTransactions in Connection with Share Buy-back ProgramMarch 9, 2026 | globenewswire.comHow The Genmab (CPSE:GMAB) Narrative Is Shifting As 2026 Catalyst Risks BuildMarch 4, 2026 | finance.yahoo.comCorrection to Company Announcement No. 13 of March 2, 2026March 2, 2026 | globenewswire.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsMarch 2, 2026 | globenewswire.comGenmab (CPSE:GMAB) Valuation Check After Recent Share Price WeaknessFebruary 28, 2026 | finance.yahoo.comIs Genmab (CPSE:GMAB) Pricing Look Attractive After Recent Share Price WeaknessFebruary 28, 2026 | finance.yahoo.comTransactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated personsFebruary 27, 2026 | globenewswire.comGrant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in GenmabFebruary 27, 2026 | globenewswire.com Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMAB Media Mentions By Week GMAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMAB News Sentiment▼0.300.44▲Average Medical News Sentiment GMAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMAB Articles This Week▼26▲GMAB Articles Average Week Get the Latest News and Ratings for GMAB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Genmab A/S and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Takeda Pharmaceutical News Today argenex News Today Teva Pharmaceutical Industries News Today BeOne Medicines News Today Revolution Medicines News Today BioNTech News Today Insmed News Today Moderna News Today Roivant Sciences News Today Viatris News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMAB) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYou have until June 1Macroeconomic strategist Dr. Mark Skousen believes June 1 marks a critical turning point for one of the most o...The Oxford Club | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
